Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c; Lifts Revenue Outlook
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $225.92 +0.56%
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $5.17, $0.51 better than the analyst estimate of $4.66. Revenue for the quarter came in at $940.65 million versus the consensus estimate of $939.97 million.
GUIDANCE:
Jazz Pharmaceuticals raises FY2022 revenue midpoint to $3.65 billion, versus the consensus of $3.65 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Sun Communities names Ileana McAlary as general counsel and EVP
- Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
